

AMENDMENTS TO THE CLAIMS



**This listing of claims will replace all prior versions and listings of claims in the application:**

**LISTING OF CLAIMS:**

**1. - 6. (canceled).**

7. (currently amended): A method for preparing a pyrazolopyrimidinethione derivative of claim 21, comprising:

reacting the compound of formula III with the compound of formula IV to give said pyrazolopyrimidinethione derivative;



wherein: in the compounds of formulas III and IV, R<sub>1</sub>, R<sub>2</sub>, and R<sub>3</sub> are same or different, and independently are alkyl having 1-6 carbon atoms, alkyl having 1-6 carbon atoms in which at least one hydrogen atom is substituted by alkoxy having 1-6 carbon atoms or cycloalkyloxy having 3-6 carbon atoms, alkenyl having 2-6 carbon atoms, or aryl having 6-10 carbon atoms;

R<sub>4</sub> is alkyl having 1-6 carbon atoms, alkenyl having 2-6 carbon atoms, alkoxy having 1-6 carbon atoms, cycloalkyloxy having 3-6 carbon atoms, or aryl having 6-10 carbon atoms;

R<sub>5</sub> is hydrogen, alkyl having 1-6 carbon atoms, alkenyl having 2-6 carbon atoms, aryl having 6-10 carbon atoms, or alkyl having 1-6 carbon atoms;

R<sub>6</sub> is hydrogen, alkyl having 1-6 carbon atoms, alkenyl having 3-6 carbon atoms, cycloalkyl having 3-8 carbon atoms, or alkyl having 1-6 carbon atoms; and


Y is Cl, F, Br, or I.

8. (original): The method according to claim 7, characterized in that: a solvent is used in the reaction and comprises at least one of chloroform, tetrahydrofuran, dioxane, ethanol, 1,2-dimethoxyethane, xylene, toluene, dimethyl sulfoxide, or triethylamine.


9. (currently amended): A method for preparing a pyrazolopyrimidinethione derivate of claim 21, comprising:

firstly reacting the compound of formula V with the compound of formula IV to give the compound of formula VI, and


then sulfurizing said compound of formula VI to give said pyrazolopyrimidinethione derivatives;



(V)



(IV)



(VI)

wherein: in the compounds of formula IV, V, and VI, R<sub>1</sub>, R<sub>2</sub>, and R<sub>3</sub> are same or different, and independently are alkyl having 1-6 carbon atoms, alkyl having 1-6 carbon atoms in which at least one hydrogen atom is substituted by alkoxy having 1-6 carbon atoms or cycloalkyloxy having 3-6 carbon atoms, alkenyl having 2-6 carbon atoms, or aryl having 6-10 carbon atoms;

R<sub>4</sub> is alkyl having 1-6 carbon atoms, alkenyl having 2-6 carbon atoms, alkoxy having 1-6 carbon atoms, cycloalkyloxy having 3-6 carbon atoms, or aryl having 6-10 carbon atoms;

R<sub>5</sub> is hydrogen, alkyl having 1-6 carbon atoms, alkenyl having 2-6 carbon atoms, aryl having 6-10 carbon atoms, or alkyl having 1-6 carbon atoms;

R<sub>6</sub> is hydrogen, alkyl having 1-6 carbon atoms, alkenyl having 3-6 carbon atoms, cycloalkyl having 3-8 carbon atoms, or alkyloyl having 1-6 carbon atoms; and

Y is Cl, F, Br, or I.

10. (original): The method according to claim 9, characterized by: using a solvent for sulfurization reaction comprising at least one of tetrahydrofuran, dioxane, 1,2-dimethoxyethane, ethanol, xylene, toluene, dimethyl sulfoxide, or triethylamine.

11. (original): The method according to claim 10, characterized by using a sulfurating reagent for said sulfurization comprising is phosphorus pentasulfide or 2,4-Bis(p-methoxyphenyl)-1,3-dithia-2,4-diphosphetane-2,4-disulfide, and derivatives thereof, and the temperature is -20-200 °C.

12. (currently amended): A method for preparing a salt of a pyrazolopyrimidinethione derivative of claim 4, comprising reacting said pyrazolopyrimidinethione derivatives of claim 21 with the pharmaceutically acceptable acids to give said salts.

**13. - 20. (cancelled).**

21. (new): Pyrazolopyrimidinethione derivatives consisting of one of:

5-[2-methoxy-5-(cis-3,5-dimethylpiperazin-1-sulfonyl)phenyl]-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-thione;

5-[2-ethoxy-5-(cis-3,5-dimethylpiperazin-1-sulfonyl)phenyl]-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-thione;

5-[2-propoxy-5-(cis-3,5-dimethylpiperazin-1-sulfonyl)phenyl]-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-thione;

5-[2-methoxy-5-(cis-3,5-dimethylpiperazin-1-sulfonyl)phenyl]-1-ethyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-thione;

5-[2-ethoxy-5-(cis-3,5-dimethylpiperazin-1-sulfonyl)phenyl]-1-ethyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-thione; or

5-[2-propoxyl-5-(cis-3,5-dimethylpiperazin-1-sulfonyl)phenyl]-1-ethyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-thione.

22. (new): A salt of at least one pyrazolopyrimidinethione derivative according to claim 21 characterized in that: said salt is of an organic acid or an inorganic acid.

23. (new): A salt according to claim 22, characterized in that:

said salt of an organic acid comprises a citrate, a fumarate, an oxalate, a malate, a lactate, a camphorsulfonate, a p-toluenesulfonate, or a methanesulfonate; and

said salt of an inorganic acid comprises a salt of a haloid acid, a sulfate, a phosphate, or a nitrate.

24. (new): A composition comprising at least one of the pyrazolopyrimidinethione derivatives of claim 21 as the active ingredient, for treating impotence.

25. (new): A composition comprising at least one salt of a pyrazolopyrimidinethione derivative of claim 22 as the active ingredient, for treating impotence.

26. (new): A composition comprising at least one salt of a pyrazolopyrimidinethione derivative of claim 23 as the active ingredient, for treating impotence.